Eosinophilic myeloid disorders

Pierre Noel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The discovery of therapeutically relevant mutations involving platelet-derived growth factor receptors alpha and beta (PDGFRA and PDGFRB) changed the way we evaluate and treat patients with clonal eosinophilia. Despite our improved understanding of the pathobiology of clonal eosinophilia, more than 50% of patients are diagnosed with idiopathic disease, 10% to 20% with a clonal myeloid disorder, and the remainder with a lymphocytic variant. The World Health Organization classification of tumors recognized the importance of a semi-molecular classification of eosinophilc myeloid disorders and divided them into two major subgroups: (1) myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or fibroblast growth factor receptor 1 (FGFR1); and (2) chronic eosinophilic leukemia, not otherwise specified. A key challenge remains the identification of tyrosine kinase responsive molecular lesions in patients in whom the pathogenesis of clonal eosinophilia remains unclear.

Original languageEnglish (US)
Pages (from-to)120-127
Number of pages8
JournalSeminars in Hematology
Volume49
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Eosinophilia
Platelet-Derived Growth Factor beta Receptor
Receptor, Fibroblast Growth Factor, Type 1
Platelet-Derived Growth Factor alpha Receptor
Protein-Tyrosine Kinases
Neoplasms
Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Eosinophilic myeloid disorders. / Noel, Pierre.

In: Seminars in Hematology, Vol. 49, No. 2, 04.2012, p. 120-127.

Research output: Contribution to journalArticle

Noel, Pierre. / Eosinophilic myeloid disorders. In: Seminars in Hematology. 2012 ; Vol. 49, No. 2. pp. 120-127.
@article{dfe48bf3cc7c4da788727086b86dfce7,
title = "Eosinophilic myeloid disorders",
abstract = "The discovery of therapeutically relevant mutations involving platelet-derived growth factor receptors alpha and beta (PDGFRA and PDGFRB) changed the way we evaluate and treat patients with clonal eosinophilia. Despite our improved understanding of the pathobiology of clonal eosinophilia, more than 50{\%} of patients are diagnosed with idiopathic disease, 10{\%} to 20{\%} with a clonal myeloid disorder, and the remainder with a lymphocytic variant. The World Health Organization classification of tumors recognized the importance of a semi-molecular classification of eosinophilc myeloid disorders and divided them into two major subgroups: (1) myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or fibroblast growth factor receptor 1 (FGFR1); and (2) chronic eosinophilic leukemia, not otherwise specified. A key challenge remains the identification of tyrosine kinase responsive molecular lesions in patients in whom the pathogenesis of clonal eosinophilia remains unclear.",
author = "Pierre Noel",
year = "2012",
month = "4",
doi = "10.1053/j.seminhematol.2012.01.008",
language = "English (US)",
volume = "49",
pages = "120--127",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Eosinophilic myeloid disorders

AU - Noel, Pierre

PY - 2012/4

Y1 - 2012/4

N2 - The discovery of therapeutically relevant mutations involving platelet-derived growth factor receptors alpha and beta (PDGFRA and PDGFRB) changed the way we evaluate and treat patients with clonal eosinophilia. Despite our improved understanding of the pathobiology of clonal eosinophilia, more than 50% of patients are diagnosed with idiopathic disease, 10% to 20% with a clonal myeloid disorder, and the remainder with a lymphocytic variant. The World Health Organization classification of tumors recognized the importance of a semi-molecular classification of eosinophilc myeloid disorders and divided them into two major subgroups: (1) myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or fibroblast growth factor receptor 1 (FGFR1); and (2) chronic eosinophilic leukemia, not otherwise specified. A key challenge remains the identification of tyrosine kinase responsive molecular lesions in patients in whom the pathogenesis of clonal eosinophilia remains unclear.

AB - The discovery of therapeutically relevant mutations involving platelet-derived growth factor receptors alpha and beta (PDGFRA and PDGFRB) changed the way we evaluate and treat patients with clonal eosinophilia. Despite our improved understanding of the pathobiology of clonal eosinophilia, more than 50% of patients are diagnosed with idiopathic disease, 10% to 20% with a clonal myeloid disorder, and the remainder with a lymphocytic variant. The World Health Organization classification of tumors recognized the importance of a semi-molecular classification of eosinophilc myeloid disorders and divided them into two major subgroups: (1) myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or fibroblast growth factor receptor 1 (FGFR1); and (2) chronic eosinophilic leukemia, not otherwise specified. A key challenge remains the identification of tyrosine kinase responsive molecular lesions in patients in whom the pathogenesis of clonal eosinophilia remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=84858779837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858779837&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2012.01.008

DO - 10.1053/j.seminhematol.2012.01.008

M3 - Article

C2 - 22449622

AN - SCOPUS:84858779837

VL - 49

SP - 120

EP - 127

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2

ER -